Abstract:Background Effective adjuvant treatment after hepatectomy for hepatocellular carcinoma (HCC) is an important area of research. Radioactive iodine (I-131)-labelled metuximab is a radiolabelled monoclonal antibody against the CD147 (also known as basigin or HAb18G) antigen that is expressed in HCC. We aimed to examine the role of I-131-metuximab as an adjuvant therapy after HCC resection. Methods This randomised, controlled, multicentre, open-label, phase 2 trial was done at five medical centres in China. Patients aged 18-75 years who underwent curative-intent resection of histologically confirmed HCC expressing CD147 were randomly assigned (1:1) by a computer-generated random sequence, stratified by centre, to receive either adjuvant transarterial injection of one dose of 27.75 MBq/kg I-131-metuximab 4-6 weeks after the hepatectomy (treatment group) or no adjuvant treatment (control group). Patients and physicians were not masked to the study groups. The primary outcome was 5-year recurrence-free survival (RFS) in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT00819650. Findings Between April 1, 2009, and Nov 30, 2012, 485 patients were screened for eligibility. 329 (68%) of these patients were excluded and 156 (32%) were randomly assigned to receive either I-131-metuximab (n=78) or no adjuvant treatment (n=78). The median follow-up was 55.9 months (IQR 18.6-79.4). In the intention-to-treat population, the 5-year RFS was 43.4% (95% CI 33.6-55.9) in the I-131-metuximab group and 21.7% (14.2-33.1) in the control group (hazard ratio 0.49 [95% CI 0.34-0.72]; Z=2.96, p=0.0031). I-131-metuximab-associated adverse events occurred within the first 4 weeks in 34 (45%) of 76 patients, seven (21%) of whom had grade 3 or 4 adverse events. These adverse events were all resolved with appropriate treatment within 2 weeks of being identified. Interpretation Adjuvant I-131-metuximab treatment significantly improved the 5-year RFS of patients after hepatectomy for HCC tumours expressing CD147. This treatment was well tolerated by patients. Copyright (C) 2020 Elsevier Ltd. All rights reserved.

Biodistribution and Localization of Iodine-131-Labeled Metuximab in Patients with Hepatocellular Carcinoma

Targeting Radioimmunotherapy of Hepatocellular Carcinoma with Iodine (131I) Metuximab Injection: Clinical Phase I/II Trials

Dosimetry of 131I labeled metuximab and transarterial chemoembolization for treatment of hepatocellular carcinoma

Evaluation of Tumor Vascular Targeting Agents Labelled with 131I in Imaging of Tumor

Patient Dosimetry for 131I -Labeled Anti-HCC Mab (Hepama-1)

Pharmacokinetics of ~(131)I-Labeled-metuximab and Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma

Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients.

Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial

Hepatic Artery Injection of <SUP>131</SUP>I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial

Hepatic Artery Injection of 131 I-labelled Metuximab Combined with Chemoembolization for Intermediate Hepatocellular Carcinoma: a Prospective Nonrandomized Study

Evaluation of radioimmunoimaging during radioimmunotherapy with monoclonal anti-human hepatocellular carcinoma antibodies

Treatment of Hepatocellular Carcinoma by Intratumoral Injection of 125I-AA98 Mab and Its Efficacy Assessments by Molecular Imaging.

Radioimmunoimaging of human hepatocellular carcinoma xenografts with 131I-anti-HBx monoclonal antibody

Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation.

Adjuvant 131I-Metuximab for Hepatocellular Carcinoma after Liver Resection: a Randomised, Controlled, Multicentre, Open-Label, Phase 2 Trial.

Phase I Clinical Trial of Targeted Therapy Using 131I-Hepama-1 Mab in Patients with Hepatocellular Carcinoma

[Biological Distribution of 131I-Hab18f(ab')2 in Patients with Hepatocellular Carcinoma].

[Pharmacokinetics of Injection of Iodine-131 Labelling MEI-TUO-XI Monoclonal Antibody in Human Body].

Bio-distribution and tumor targeting of 131 I-rMIF in tumor-bearing mice

Radioiodinated Anti-Hepatocellular Carcinoma (HCC) Ferritin Targeting Therapy, Tumor Imaging and Anti-Antibody Response in HCC Patients with Hepatic Arterial Infusion

Evaluation of Iodine-125 Interstitial Brachytherapy Using Micro-Positron Emission Tomography/Computed Tomography with 18F-Fluorodeoxyglucose in Hepatocellular Carcinoma HepG2 Xenografts